Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i
A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre
The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c
This review analyzes findings from the pan-European SHARP registry study, identifying distinct multimorbidity phenotypes in severe asthma. It highlights the impact of steroid-associated and sinonasal clusters on clinical outcomes, advocatin
Researchers have developed a first-in-class antibody-drug conjugate targeting High Endothelial Venules via the CHST4 enzyme. This therapy promotes regulatory T cell induction and long-term heart transplant survival in murine models using si
Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient
The Phase 3 LIBERTY-CSU CUPID trials demonstrate that dupilumab significantly reduces itch and hives in patients with chronic spontaneous urticaria uncontrolled by antihistamines, providing a crucial new therapeutic option for those who are
The WAYFINDER study reveals that tezepelumab significantly reduces OCS dependence in severe asthma, with over half of patients achieving complete discontinuation by week 52 while maintaining asthma control, regardless of baseline inflammato
The INFORM ASTHMA trial demonstrates that budesonide-formoterol as a reliever significantly reduces Type 2 airway inflammation (FeNO) compared to terbutaline in adults already using maintenance inhaled corticosteroids, establishing a new ev
The PIPPA Tamariki randomized controlled trial demonstrates that using paracetamol versus ibuprofen as needed in the first year of life does not significantly alter the risk of developing eczema or bronchiolitis by age one, challenging long
This comprehensive systematic review and meta-analysis of 190 studies involving 2.8 million participants establishes a 4.7% incidence rate for childhood food allergy and identifies early atopic conditions, microbiome disruptions, and delaye
Recent findings from the COPSAC2010 trial and EDEN cohort suggest that high-dose prenatal vitamin D’s protective effect against atopic dermatitis is significantly enhanced in children of mothers exposed to tobacco, highlighting a pote
A groundbreaking study shows that CD19 CAR T-cell therapy can induce sustained, drug-free remission in patients with severe, multirefractory autoimmune hemolytic anemia by successfully eliminating the autoreactive B-cells that drive the dis
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inf
A Phase 1 trial published in NEJM Evidence demonstrates that allogeneic, umbilical cord-derived regulatory T cells are safe and potentially effective in slowing the progression of ALS, providing a scalable, off-the-shelf alternative to trad
This case report explores the immunomodulatory effects of teplizumab in two adolescents with APS-1-associated stage 2 T1D, highlighting potential for preservation of β-cell function.
The BAT2 study reveals that the Basophil Activation Test (BAT) is the only biomarker capable of accurately predicting reaction severity to baked milk and the sensitivity threshold for fresh milk, offering a transformative tool for clinical
The FDA has approved depemokimab (Exdensur), the first long-acting biologic for severe eosinophilic asthma. Requiring only two doses per year, it significantly reduces exacerbations and hospitalizations, offering a transformative shift in t
A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target r
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
Open language-specific specialty feeds and department pages.